The accreditors of this session require that you periodically check in to verify that you are still attentive.
Please click the button below to indicate that you are.
SOCIETY: AGA This session is the second session of the ever-popular and clinically impactful clinical trials sessions in IBD. Insights into novel agents including obefazimod, VTX002. MH002, risankizumab, and mirikizumab will be presented…
SOCIETY: AGA In this session, several clinically relevant presentations will put the attendee at the cutting edge of research and clinical care, with regard to stem cells for perinal fistulas, biologic de-escalation, subcutaneous biologics, and use of small molecules in microscopic colitis
SOCIETY: AGA Small molecules are a new exicting therapeutic class in IBD that may have potential safety signals which have not been well described in the real world…